Day: October 21, 2020

Harvest Health & Recreation Inc. Announces C$30,000,000 Million Bought Deal Financing

** THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.**PHOENIX, Oct. 21, 2020 (GLOBE NEWSWIRE) — Harvest Health & Recreation Inc.    (“Harvest” or the “Company”)   (CSE: HARV), a vertically integrated cannabis company and multi-state operator in the U.S., is pleased to announce that is has entered into an agreement pursuant to which Eight Capital, as lead agent and bookrunner, together with a syndicate of underwriters (collectively, the “Underwriters”), will purchase on a “bought deal” basis 13,274,400 units of the Company (“the Units”) at a price of $2.26 per Unit (the “Offering Price) for aggregate gross proceeds to Harvest of $30,000,144 (the “Offering”). (All figures are in Canadian dollars unless otherwise...

Continue reading

Savaria Presents a Preview of Third Quarter Results

LAVAL, Quebec, Oct. 21, 2020 (GLOBE NEWSWIRE) — Savaria Corporation (“Savaria”) (TSX: SIS) one of the global leaders in the accessibility industry, believes that it is important, due to the ongoing COVID-19 pandemic and unprecedented financial disturbance in the market, to provide an update to its shareholders and stakeholders with respect to its 2020 third quarter financial results.Revenue is expected to be approximately $90 million, down 6% from the same period in 2019, while adjusted EBITDA is expected to increase by 8% to reach approximately $17 million, compared with $15.7 million in the third quarter of 2019.For the nine-month period ended September 30, 2020, revenue is expected to be approximately $263 million, representing a 5% decrease over the same period of 2019. Adjusted EBITDA should be approximately $44 million, an...

Continue reading

Savaria présente un aperçu de ses résultats du troisième trimestre

LAVAL, Québec, 21 oct. 2020 (GLOBE NEWSWIRE) — Corporation Savaria (« Savaria ») (TSX: SIS) un des chefs de file mondiaux de l’industrie de l’accessibilité, estime qu’il est important, en raison de la pandémie de COVID-19 qui perdure et des perturbations sans précédent sur les marchés financiers, d’informer ses actionnaires et parties prenantes de ses résultats financiers du troisième trimestre 2020.Les revenus devraient s’élever à environ 90 millions de dollars, en baisse de 6 % par rapport à la même période en 2019, tandis que le BAIIA ajusté devrait augmenter de 8 % pour atteindre environ 17 millions de dollars contre 15,7 millions de dollars au troisième trimestre de 2019.Pour la période de neuf mois se terminant le 30 septembre 2020, les revenus devraient s’élever à environ 263 millions de dollars, en baisse de 5 % par rapport...

Continue reading

Allakos Announces Publication of Results from the Phase 2 Study of Lirentelimab (AK002) in Patients with Eosinophilic Gastritis and/or Eosinophilic Duodenitis (ENIGMA) in the New England Journal of Medicine

REDWOOD CITY, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) — Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced the publication of results from the multicenter, randomized, double-blind, placebo-controlled Phase 2 study of lirentelimab (AK002) in patients with eosinophilic gastritis and/or eosinophilic duodenitis (ENIGMA) in the New England Journal of Medicine (NEJM). All AK002 dose arms showed clinically meaningful and statistically significant benefits compared to placebo on all prespecified primary and secondary endpoints, including gastrointestinal tissue eosinophil counts and patient-reported disease symptoms. Previously announced, top-line data from the study are available here. The peer-reviewed article, “Anti-Siglec-8...

Continue reading

Dril-Quip, Inc. Schedules Third Quarter 2020 Earnings Release and Upcoming Webcast

HOUSTON, Oct. 21, 2020 (GLOBE NEWSWIRE) — Dril-Quip, Inc. (NYSE: DRQ), (the “Company” or “Dril-Quip”) announced today that it will release its third quarter 2020 earnings press release following the market close on Thursday, October 29, 2020. The Company will also participate in a fireside chat webcast conversation with Taylor Zurcher and George O’Leary of Tudor, Pickering, Holt & Co. on Friday, October 30, 2020 at 11:00 a.m. Eastern Time (10:00 a.m. Central Time).Blake DeBerry, Dril-Quip’s Chief Executive Officer, and Raj Kumar, Dril-Quip’s Vice President and Chief Financial Officer, will be discussing multiple topics regarding the Company’s recent financial performance, current operations and business outlook with Mr. Zurcher and Mr. O’Leary. There will be no questions and answers from other participants during the event,...

Continue reading

Martin Midstream Partners Reports Third Quarter 2020 Financial Results and Declares Quarterly Cash Distribution

Financial performance exceeds expectations in challenging environmentReported net loss of $10.8 million and $4.2 million for the three and nine months ended September 30, 2020, respectively, which were negatively impacted by an $8.5 million charge related to the exchange of our senior notesReported adjusted EBITDA of $22.5 million and $77.5 million for the three and nine months ended September 30, 2020, respectivelyGenerated distributable cash flow of $8.1 million and $38.9 million for the three and nine months ended September 30, 2020, respectivelySuccessfully completed exchange offer and cash tender offer of senior notesAffirms guidance range for adjusted EBITDA and capital expendituresKILGORE, Texas, Oct. 21, 2020 (GLOBE NEWSWIRE) — Martin Midstream Partners L.P. (Nasdaq:MMLP) (the “Partnership”) today announced its...

Continue reading

Rice Acquisition Corp. Announces Pricing of Initial Public Offering

CARNEGIE, Pennsylvania, Oct. 21, 2020 (GLOBE NEWSWIRE) — Rice Acquisition Corp.  (the “Company”) announced today the pricing of its initial public offering (“IPO”) of 20,000,000 units at a price of $10.00 per unit. The units will be listed on the New York Stock Exchange (the “NYSE”) and trade under the ticker symbol “RICE U” beginning on October 22, 2020. Each unit consists of one share of the Company’s Class A common stock and one-half of one redeemable warrant, with each whole warrant entitling the holder thereof to purchase one share of the Company’s Class A common stock at an exercise price of $11.50 per share. Once the securities comprising the units begin separate trading, the shares of Class A common stock and warrants are expected to be listed on the NYSE under the symbols “RICE” and “RICE WS,” respectively.Barclays is acting...

Continue reading

Genmab Announces IFM, HOVON and Janssen Achieve Positive Topline Results in Second Part of Phase 3 CASSIOPEIA Study of Daratumumab in Multiple Myeloma at Pre-planned Interim Analysis

Company AnnouncementSecond part of the Phase 3 CASSIOPEIA study of daratumumab as maintenance treatment for patients with newly diagnosed multiple myeloma eligible for autologous stem cell transplant met the primary endpoint of progression-free survival at a pre-planned interim analysisIndependent Data Monitoring Committee recommends unblinding the study resultsBased on the data, Janssen plans to discuss the potential for a regulatory submission with health authoritiesCopenhagen, Denmark; October 21, 2020 – Genmab A/S (Nasdaq: GMAB) announced today positive topline results from the second part of the Phase 3 CASSIOPEIA (MMY3006) study of daratumumab monotherapy as maintenance treatment versus observation (no treatment) for patients with newly diagnosed multiple myeloma eligible for autologous stem cell transplant (ASCT). The second part...

Continue reading

Sun Communities, Inc. Reports 2020 Third Quarter Results

NEWS RELEASEOctober 21, 2020Southfield, Michigan, Oct. 21, 2020 (GLOBE NEWSWIRE) — Sun Communities, Inc. (NYSE: SUI) (the “Company”), a real estate investment trust (“REIT”) that owns and operates, or has an interest in, manufactured housing (“MH”) and recreational vehicle (“RV”) communities, today reported its third quarter results for 2020.Financial Results for the Quarter and Nine Months Ended September 30, 2020For the quarter ended September 30, 2020, total revenues increased $38.1 million, or 10.5 percent, to $400.5 million compared to $362.4 million for the same period in 2019. Net income attributable to common stockholders was $81.2 million, or $0.83 per diluted common share, for the quarter ended September 30, 2020, as compared to net income attributable to common stockholders of $57.0 million, or $0.63 per diluted common...

Continue reading

GBLT Insiders Agree to Debt Conversion

DUEREN, Germany, Oct. 21, 2020 (GLOBE NEWSWIRE) — GBLT Corp. (“GBLT” or the “Company”) ‎‎(TSXV:GBLT; ‎‎OTCQB:GBLTF; FSE: 4G9), announces that its four directors have agreed to accept shares in lieu of cash in respect of ‎director sitting fees for the three months ended September 30, 2020. Accordingly, each director has agreed to accept 55,555 common shares in satisfaction of CAD$3,750 of indebtedness owed to such director. The Company determined (with the consent of the directors) to satisfy the foregoing indebtedness with common shares in order to preserve ‎its cash. The transactions are subject to execution of debt conversion agreements and approval of the TSX Venture Exchange. In addition, such ‎shares will be subject to a Canadian four-month hold period.‎The shares for debt transactions by the four directors (Dr. Thilo Senst,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.